

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re CIP of Patent Application Serial No.08/765,337 of

YOKOI et al

Atty. Ref.: 249-118

Serial No. to be assigned

Group: 1646

Filed: October 6, 2000

Examiner: Mertz

For: HG-CSF FUSION POLYPEPTIDE HAVING C-MPL  
ACTIVITY, DNA CODING FOR SAME AND METHODS  
OF TREATING ANEMIA USING SAME(AS AMENDED)

\* \* \* \* \*

October 6, 2000

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. § 1.55 and in conformance with the procedures of 37 C.F.R. § 1.98, applicants hereby bring the following references<sub>[isp2]</sub> to the attention of the examiner. These references<sub>[isp3]</sub> are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references<sub>[isp4]</sub> be made of record therein and appear among the "References Cited" on any patent to issue therefrom. A copy of the patent, publication or other information listed on the modified PTO form 1449 is enclosed.

Please return to the undersigned a copy of the attached PTO-1449 with the examiner's initials in the left column [MPEP § 609] with the next communication.



“ YOKOI et al  
Serial No. to be assigned

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Arthur R. Crawford

Reg. No. 25,327

ARC:pfc  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100